Lilly to us is going to emerge as the drug company of the decade.
Warner-Lambert is trying to maximize the price paid for the company. They think that they are entitled to a higher price, and this facilitates that.
Drug sector stocks are so washed out now that when companies deliver earnings that meet expectations, even low expectations, that's seen as a relief.
There's isolated incidents of companies (warning) because of patent expiration or pipeline problems or both, but they are very isolated.